CDK8-IN-19

• Description:

  CDK8-IN-19 (Compound 3d) is a CDK8 inhibitor with an IC50 of 25.08 nM. CDK8-IN-19 has a broad-spectrum anticancer activity, such as leukemia, melanoma and breast cancer, without significant cytotoxic effect on the normal Vero cells (mean IC50s of 2.87, 3.65, 3.79 and 45.48 μM, respectively) [1].

• UNSPSC:

  12352005

• Target:

  CDK; PI3K

• Related Pathways:

  Cell Cycle/DNA Damage; PI3K/Akt/mTOR

• Field of Research:

  Cancer

• Smiles:

  S=C (NC1=CC=C (Cl) C=C1Cl) NC (S/C2=C/C3=CC=CC=C3) =NC2=O

• Molecular Formula:

  C17H11Cl2N3OS2

• Molecular Weight:

  408.32

• References & Citations:

  [1]Mohamed AR, et al. Integrated structure- and ligand-based design, synthesis, and biological evaluation of potent thiazole-based multi-kinase PI3Kα and CDK2/8 inhibitors as anticancer agents. Eur J Med Chem. 2025 Oct 15;296:117902.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK2; CDK8; PI3Kα